Introducing
Your new presentation assistant.
Refine, enhance, and tailor your content, source relevant images, and edit visuals quicker than ever before.
Trending searches
248
227
+9.25%
Eris Lifesciences posted a decent set of earnings performance. Consolidated total income increased by 9.25% at Rs. 247.50 Crs as compared to Rs. 226.55 Crs in the corresponding quarter previous year. Sale of products grew by 15.63% whereas other operating income increased by 19.94% on a YoY basis.
In Q4FY20, Chronic segment constitutes 65% of Company's revenue, Sub-chronic segment constitutes 22% of revenue and Acute segment is 13% of Company's revenue.
Chronic therapies continue to outperform market and sub chronic therapies regain momentum: chronic therapies grow 19.6% YoY vs. IPM growth of 12.1% whereas sub chronic therapies grow 13.4% YoY vs. IPM growth of 7.3%.
76
74
+3.10%
The company reported increase in EBITDA by 3.10% to Rs. 76.17 Crs as compared to Rs. 73.88 Crs in the previous year same quarter.
Company's EBITDA margin stood at 30.77%
56
54
+4.43%
Company reported a consolidated profit of Rs. 56.27 Crs vs. Rs. 53.88 Crs in the corresponding quarter previous year, a jump of 4.43%.
Cash flow from operations improved during the FY2019-20 with net cash inflow from operations of Rs. 271.11 Crs vs. Rs. 223 Crs during FY2018-19.
PREVIOUS
CURRENT
248
227
BEATS
REVENUE
-9.25%
76
74
+3.10%
BEATS
EBITDA
56
54
+4.43%
BEATS
PROFIT